Ten Steps to Advance Biomarker Testing

Matching patients with the most effective therapies for their cancer can require testing tumors for genetic mutations or expression of the proteins that certain drugs target. However, tests for these biomarkers can vary in quality, and evidence of their clinical value may be lacking. A recently issued report from the Institute of Medicine outlines 10 interrelated recommendations to resolve these and other concerns about biomarker testing-and more fully implement personalized medicine.